NYU Langone Shows Positive Results for Phase 1 Study Demonstrating Merck Virus Therapy Holds Promise Against Inoperable Skin Cancers

NYU Langone Shows Positive Results for Phase 1 Study Demonstrating Merck Virus Therapy Holds Promise Against Inoperable Skin Cancers

A Phase 1 clinical trial led by an investigator at NYU Langone and its Perlmutter Cancer Center report positive results from a new combination drug therapy, evidencing safety and efficacy against advanced skin cancer in patients who were not able to have their tumors surgically removed. This particular drug combination is one of the first to demonstrate the possibility of a live common cold virus known as coxsackievirus, used to infect and kill cancer cells. The study results also reveal how oncolytic viruses can safely boost the action of widely used cancer therapies to help the body’s immune defense system identify and kill cancer cells. To date, these immunotherapies only help shrink melanoma tumors (skin cancer) in just over a third of patients who receive such treatment. 

Background

Scientists have known since the 1800s that some cancer patients who suffered from infections, later tied to bacteria or viruses that cause measles and herpes, often experience tumor shrinkage. Recent technological advances in genetic engineering have allowed scientists to retool viruses to target specific molecules on the surface of cancer cells to more easily infect them.

Trial Site Orga...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee